• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

PHASE I CLINICAL TRIALS FOR PSORIASIS TX

Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
Related Content
Suicide Risk Management Crucial in Dermatological Care
May 22nd 2025

Suicide Risk Management Crucial in Dermatological Care

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
May 20th 2025

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Quoin Receives FDA Clearance for Second Netherton Trial
May 22nd 2025

Quoin Receives FDA Clearance for Second Netherton Trial

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine
March 31st 2025

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial
May 22nd 2025

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial

Cutibacterium acnes Dominates the Post-Laser Skin Microbiome
May 22nd 2025

Cutibacterium acnes Dominates the Post-Laser Skin Microbiome

© 2025 MJH Life Sciences

All rights reserved.